Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 202 for “"TKIs"”.
-
Exploring the Senomimetic Effects of TKIs as Primers for Immune Responses
Tyrosine kinase inhibitors (TKIs) capable of blocking the vascular endothelial growth factor receptor (VEGFR) pathway aim to limit tumor angiogenesis. These drugs have been approved to treat multiple metastatic cancers, but it has become clear that their effects extend beyond angiogenesis and can …
-
Δερματολογική τοξικότητα από EGFR-TKIs θεραπεία σε ασθενείς με καρκίνο πνεύμονα
Το καρκίνωμα του πνεύμονα αποτελεί την κύρια αιτία θανάτου από καρκίνωμα σε όλες τις ανεπτυγμένες χώρες. Η συνολική 5-ετής επιβίωση των ασθενών είναι μικρότερη του 15%. Η θνητότητα από καρκίνωμα του πνεύμονα είναι μεγαλύτερη από το σύνολο της θνητότητας του καρκινώματος του μαστού, του προστάτη και …
-
EXPLORING THE ROLE OF PHARMACOKINETIC ALTERATIONS IN TYROSINE KINASE INHIBITORS (TKIS)-ASSOCIATED TOXICITIES
… While the use of tyrosine kinase inhibitors (TKIs) have largely mitigated the conventional toxicities of chemotherapeutic agents, a range of previously unknown and sometimes unpredictable toxicities like cutaneous, cardiac and liver toxicities began to surface. Furthermore, several new issues …
-
Synergistic Interaction of JTE-607 with EGFR-TKIs (Afatinib and Osimertinib) in Non-Small Cell Lung Cancer Cell Lines H1975 and HCC827: A Therapeutic Investigation
… due to resistance to tyrosine kinase inhibitors (TKIs) in cases with epidermal growth factor receptor (EGFR) mutations, including T790M. This study investigates the synergistic interaction of the small molecule inhibitor JTE-607 with Afatinib and Osimertinib to enhance TKI efficacy, to reduce …
-
Correlation of Thyroid Transcription Factor-1 (TTF-1) expression with response rate to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with lung adenocarcinoma
… βασίζεται στο γενετικό προφίλ των όγκων. Οι EGFR TKIs σηματοδότησαν την εξέλιξη αυτή, όταν όγκοι με μετάλλαξη του EGFR γονιδίου παρουσίασαν σημαντική ανταπόκριση σε αυτούς τους παράγοντες. Ο TTF-1 είναι ένας μεταγραφικός παράγοντας πολλών σημαντικών γονιδίων στον πνεύμονα και τον θυρεοειδή αδένα. …
-
Targeting the MIF-CD74 axis to overcome resistance to tyrosine kinase inhibitors in lung cancer
Development of tyrosine kinase inhibitors (TKIs) against oncogenic drivers has significantly improved survival of patients with oncogene-mutated non-small cell lung cancer (NSCLC). However, acquired resistance to TKIs emerges over time in essentially all patients who initially respond. Recent …
-
Cardiotoxicity of Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors (TKIs) have been an increasingly popular new form of cancer treatment. With the development of many new TKIs designed to target specific malignancies, there is increased need to examine their possible toxicities. Many of these TKIs are said to have selective targeting …
-
Biologic and Therapeutic Studies to Improve the Anti-tumor Efficacy of Antiangiogenic Tyrosine Kinase Inhibitors
Antiangiogenic tyrosine kinase inhibitors (TKIs), unlike VEGF pathway-targeting antibodies, have failed to show meaningful antitumor efficacy in most solid cancer types, even when combined with standard chemotherapy. The overall goal of the studies undertaken for this thesis was to study various …
-
Preclinical and clinical characterization of lung cancers with Exon 19 insertion
… 19 PVAI amino-acid insertions to available EGFR TKIs. A limited number of preclinical and clinical reports have studied the response of these mutants to all classes of approved EGFR TKIs. We used models of EGFR-K745_E746insIPVAIK and more typical EGFR mutations (exon 19 deletion, L858R, L861Q, …
-
Modeling targeted therapy mechanisms and predictive biomarker discovery using human primary non-small cell lung cancer xenografts
… (EGFR) gene. Tyrosine kinase inhibitors (TKIs) have significantly improved clinically outcomes in lung cancer patients with these activating EGFR mutations. However, EGFR TKIs are not a cure as the vast majority of patients develop resistance. Some mechanisms of resistance to EGFR TKIs …
-
Regulation of blood glucose by xenobiotic and microbial impactors of RIPK2 signalling
… For example, tyrosine kinase inhibitors (TKIs) are being investigated for diabetes treatment. Improvements in blood glucose control have been observed in diabetic cancer patients receiving TKI therapy but the mechanism underlying these changes remains unclear. Several TKIs inhibit RIPK2. …
-
Towards Novel Effective Combination Therapy for KRAS Mutant Non-Small Cell Lung Cancer
… via EGFR-Tyrosine Kinase inhibitors (EGFR-TKIs) is a main therapeutic strategy. However, patients with mutations in KRAS are resistant to EGFR-TKIs. A study in mutant KRAS-driven lung cancer in transgenic mice showed that tumor growth was dependent on the activity of focal adhesion kinase …
-
The role of CD74 in the development of resistance to tyrosine kinase inhibitors in ROS1- and ALK-fusion non-small cell lung cancer
… of efficacious tyrosine kinase inhibitors (TKIs) provides an encouraging push towards the treatment of non-small cell lung cancer (NSCLC) with oncogenic drivers, the development of drug resistance in tumor cells obstructs the path towards a permanent cure. The emergence of mechanisms of …
-
Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
… treated with tyrosine kinase inhibitors (TKIs). TKIs have proven effective in improving survival until resistance is conferred, mostly by way of the exon 20, threonine 790 to methionine (T790M) point mutation in EGFR. The mechanism by which this point mutation arises is poorly understood. …
-
THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND ENHANCING RESPONSE TO TARGETED EGFR THERAPY
… However, many patients treated with EGFR TKIs do not respond to therapy. The burden of failed treatment is largely placed on the healthcare field, limiting the effectiveness of EGFR TKIs. Furthermore, responses are hindered by the emergence of resistance. Thus, two questions must be …
-
Targeting autophagy in chronic myeloid leukemia through inhibition of the core autophagy protein ATG4B
… pathogenesis using tyrosine kinase inhibitors (TKIs); however, drug resistance and relapse can occur when BCR-ABL1-independant survival pathways such as autophagy are activated. Our lab found that the key autophagy enzyme ATG4B is upregulated in CML stem/progenitor cells from patients that …
-
Αναδρομική μελέτη παρατήρησης ασθενών με EGFR(+), μη μικροκυτταρικό καρκίνο του πνεύμονα, με στόχο την κλινική συσχέτιση του είδους των μεταλλάξεων του EGFR με την ανταπόκριση στη θεραπεία με τους διαθέσιμους EGFR-TKIs καθώς και ως προβλεπτικού δείκτη
… με μικρομοριακούς αναστολείς τυροσινικών κινασών(TKIs). Σκοπός: Σκοπός της παρούσας μελέτης είναι η κλινική συσχέτιση του EGFR γονότυπου με την ανταπόκριση στη θεραπεία με τους διαθέσιμους TKIs και η εκτίμηση του EGFR γονότυπου ως προβλεπτικού δείκτη. Μεθοδολογία: Εξετάστηκαν αναδρομικά 68 …
-
Einfluss der Src-kinase-Inhibitoren auf die TLR-4-induzierte IL-10 bzw. IL-12 Produktion in Tumor-assoziierten Makrophagen
… belegt werden, dass Tyrosinkinaseinhibitoren (TKIs) Einfluss auf Zellen des TME haben und vor allem die dort vorherrschenden Zellen, Tumor-assoziierte Makrophagen (TAM), durch die TKIs moduliert werden können. Sie entsprechen meist dem M2-Phänotyp, sezernieren antiinflammatorische Zytokine und …
-
Role of HER-targeted tyrosine kinase inhibitors in the treatment of high grade serous ovarian cancer
… (mAbs) and tyrosine kinase inhibitors (TKIs) targeted against the HER family have demonstrated valuable anti-tumour activity in multiple other cancer types, and their possible use in ovarian cancer merits further study. This study sought to evaluate the effectiveness of HER-targeted …
-
Belizatinib is a potent inhibitor for non-small cell lung cancers driven by different variants of EML4-ALK fusion proteins carrying L1196M-mutations
… Ba/F3 models were constructed and used for ALK-TKIs screening in this thesis. Based on cell viability assays, the results gained here suggested that brigatinib might be priority recommended for G1269A and L1152R mutations, lorlatinib for C1156Y and I1171T mutations and belizatinib for G1269A and …
Page 1 of 11